Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 1,738 trials

Urothelial Cancer: Disitamab Vedotin with Pembrolizumab

We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.

Bladder CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

SPRING Rollover: Follow-Up Study

This study is for participants from the previous SPRING trial to assess ongoing effects and safety of the treatment. We aim to gather more information on its long-term benefits.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Oncology

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Alpelisib for Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP)

We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.

PIK3CA Related Overgrowth SpectrumMegalencephaly-Capillary Malformation-Polymicrogyria Syndrome>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurologyPediatrics

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

End-Stage Kidney Disease: CSL300 Treatment Study

We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.

Atherosclerotic Cardiovascular Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Ulcerative Colitis: SAR443122 Study

We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Parkinson's Disease: ACI-7104.056 Vaccine Study

We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.

Early Stages of Parkinson's Disease>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Preventing Bronchopulmonary Dysplasia: New Treatment for Preterm Newborns

We are studying a new therapy using cell-derived vesicles to see if it can help prevent lung problems in extremely preterm newborns. This trial will assess both safety and effectiveness compared to a placebo.

Bronchopulmonary Dysplasia>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesPediatricsPulmonology

Acute Myeloid Leukemia: CPX-351 vs. Standard Chemotherapy

We are studying whether a new treatment called CPX-351 can help patients with specific types of acute myeloid leukemia achieve better remission compared to standard chemotherapy. This trial focuses on patients with de novo intermediate or adverse risk AML.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Belatacept vs. Traditional Immunosuppressants

We are studying if replacing standard medications with belatacept helps kidney transplant patients with early graft dysfunction. The goal is to see if this approach improves kidney function and reduces rejection risks.

Kidney Transplant1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Etripamil Nasal Spray for Pediatric Heart Condition

We are studying whether a nasal spray can help stop episodes of a fast heart rate in children aged 6 to 17. The trial also looks at how safe the spray is for these young patients.

Paroxysmal Supraventricular Tachycardia≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyPediatrics

Etrasimod for Adolescents with Ulcerative Colitis

We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Heart Attack Recovery: Dabigatran vs. Vitamin K Antagonist

We are studying whether the medication Dabigatran helps patients with blood clots in the heart after a heart attack recover better than a traditional treatment. This trial looks at how well each treatment resolves the clot and prevents complications.

STEMI (ST Elevation Myocardial Infarction)Left Ventricular Thrombosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Peripheral T-Cell Lymphoma: Tolinapant with Decitabine/Cedazuridine

We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.

T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Preventing Dementia: Metformin and Lifestyle Changes

We are studying whether a combination of metformin and a structured lifestyle program can help older adults at risk for dementia improve their cognitive abilities and overall health compared to a self-guided approach.

Cognitive Impairment Prevention>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyNeurology

HER2 Status in Solid Tumors: [68Ga]Ga-ABY-025 PET Study

We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.

Breast CancerGastro-esophageal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Multiple Myeloma: Isatuximab and Lenalidomide Study

We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Myelodysplastic Syndrome: Oral Azacitidine Study

We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes (MDS)>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesHematology